史上最全肿瘤分子靶向药名及对应靶点清单

2022-05-04 宁宁 MedSci原创

纯干货,赶紧收藏!

肿瘤分子靶向药物利用肿瘤细胞与正常细胞之间分子生物学上的差异,抑制肿瘤细胞的生长增殖,最后使其死亡。肿瘤分子靶向治疗将比化疗更为有效、副作用更小,是非常有希望的一种肿瘤治疗方法。
近几年,国家花大力气解决老百姓的需求,高度重视抗癌靶向药的保障情况,力争在最短时间内让患者用的起药。近两年,NMPA相关机构加快了审批进程,加快获批FDA认证的药物,让更多的患者有药可用!另一方面,中国抗肿瘤新药研发快速发展,从仿制向原研创新转变,中国告别无药时代。2021抗癌新药井喷,国内有很多款抗癌新疗法获批上市。
为此,小编特意整理最新获批的肿瘤靶向药物,按癌种分类列表,方便实用,记得收藏!
注:所有表格中(红色表示尚未在中国内地尚未上市,#表示上市未批准治疗此种癌症,黑色粗体表示在中国内地新上市,黑色粗体斜体表示国产新药)。
一、肺癌
 
图片
 
二、乳腺癌
 
图片
三、结直肠癌
图片
 
四、胃癌食管癌
图片
 
五、肝胆胰腺癌
图片
 
六、生殖系统肿瘤
图片
七、泌尿系统肿瘤
图片
 
八、血液系统肿瘤
图片
 
图片
图片 
九、头颈部癌
图片
十、皮肤软组织肿瘤
图片
十一、其他肿瘤
图片

十二、不限癌种的靶向药
 
图片

参考:https://www.cn-healthcare.com/articlewm/202107 02/content-1239086.html.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-12-09 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-08-29 医海无涯苦作舟

    学习了。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-08-24 waj970409

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 jing0309

    感谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 weigq

    👍👍👍

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 1064510_1039
  8. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 西瓜0628

    学习了#学习#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 琦琪

    谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2078083, encodeId=8d1e20e8083b4, content=<a href='/topic/show?id=eadf82828a1' target=_blank style='color:#2F92EE;'>#肿瘤分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82828, encryptionId=eadf82828a1, topicName=肿瘤分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 09 16:02:06 CST 2022, time=2022-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986948, encodeId=da7b1986948bc, content=<a href='/topic/show?id=77dd31e07c0' target=_blank style='color:#2F92EE;'>#分子靶向#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31707, encryptionId=77dd31e07c0, topicName=分子靶向)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f00658, createdName=yyanpro@21cn.c, createdTime=Fri Jun 24 14:02:06 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1241914, encodeId=c76b1241914f3, content=学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Mon Aug 29 21:28:42 CST 2022, time=2022-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1240794, encodeId=b4741240e94de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47401570839, createdName=waj970409, createdTime=Wed Aug 24 22:08:58 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217157, encodeId=0c3d121e157de, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220313/1fccd8869aca4c2bbabb274c6aada833/8cdb5c5762b54b208703fcac43dcca47.jpg, createdBy=872f5678021, createdName=jing0309, createdTime=Thu May 05 20:43:18 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216969, encodeId=b0b91216969fd, content=👍👍👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210703/9c448fe1b3b54fd7bc9477662f4861bb/4bdadad22bfd46f2921aabb4c40265d3.jpg, createdBy=a8d81938466, createdName=weigq, createdTime=Thu May 05 07:53:07 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216964, encodeId=c796121696478, content=<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#肿瘤#</a>好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82769, encryptionId=aa0582e6946, topicName=肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Thu May 05 07:15:41 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216958, encodeId=5050121695812, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/gKNgZiaia7XBE8lJLn1fp5u443yIhUNiaN9RztibctRREAGYVEtL7eC22wG0DzYdDiaiaTAEg4HaotaF4icegqk4VQvCA/132, createdBy=d6182579909, createdName=西瓜0628, createdTime=Thu May 05 06:49:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216948, encodeId=dd021216948ce, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26e71634726, createdName=琦琪, createdTime=Thu May 05 01:22:46 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216943, encodeId=46941216943e4, content=学习了 谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51038112333, createdName=ms6000001382317484, createdTime=Thu May 05 00:08:02 CST 2022, time=2022-05-05, status=1, ipAttribution=)]
    2022-05-05 ms6000001382317484

    学习了 谢谢分享

    0

相关资讯

Int Arch Allergy Immunol:TGF-β信号通路基因的MicroRNA靶点的多态性与过敏性鼻炎的易感性研究

位于3'-UTR区的microRNA靶位点内的多态性可能会引起micro-RNA结合的变化,从而调节基因的表达,并与潜在的疾病相关。

Cell:新靶点Serpin B9直接介导肿瘤杀伤和癌症免疫治疗

梅斯医学小编注:肿瘤的治疗当前的主要前沿是新的靶点的发现,一个优秀靶点发现可能成就一系列创新药物。而靶点又分为突变靶点,异常表达的biomarkers。一般认为肿瘤特异性突变的靶点,是最佳的选择,如E

Nature:非小细胞肺癌新靶点CLIP1-LTK被发现,劳拉替尼效果不错

据全球数据统计,在所有类型的癌症中,肺癌的死亡率最高,占癌症相关死亡的19%,占全球总死亡的3%。而非小细胞肺癌(NSCLC)约占肺癌总数的85%,是最常见的肺癌类型。

思路迪医药获新一代CD47抗体新药大中华区**授权

2021年3月31日,位于张江科学城上海国际医学园区的思路迪医药宣布取得ImmuneOncia Therapeutics新一代抗CD47单克隆抗体IMC-002肿瘤适应症在大中华区(中国大陆、香港、澳

Nat Commun:科学家发现肿瘤免疫治疗潜在靶点!

该研究发现了一种RBP DENR可以调节PD-L1表达以逃避肿瘤免疫,并突出了DENR作为免疫治疗靶点的潜力。